FHTX (Foghorn Therapeutics, Inc.) Price-to-Projected Revenue Ratio

The high scientific standing of Foghorn Therapeutics (FHTX) in chromatin biology ensures market confidence. The future P/S multiple valuation on GURU.Markets captures the dynamics of this demand, where the 1.10 indicator reflects the asset's status. Growth is supported by innovations in gene modulation for blood therapies and production optimization via external plants in Massachusetts.

Foghorn Therapeutics Inc. - FHTX Projected Price to Revenue (period 07/04/2022 - 11/14/2026)

FHTX (Foghorn Therapeutics, Inc.): analytical breakdowns and indicator data

- current price and projected stock value:

Stock Price Foghorn Therapeutics, Inc.|FHTX - Forecast Levels Chart

- business market valuation indicators:

Market Value Foghorn Therapeutics Inc.|FHTX - Total Enterprise Value

- book value of equity indicators:

Book Value per Share Foghorn Therapeutics|FHTX - Book Value of Business|Market Capitalization to Book Value Ratio foghorntx.com|FHTX - Aggregate Asset Value

- debt and liquidity data:

- financial results and valuation multiples details:

FHTX - Profit After Payment of Taxes|Projected Future Earnings Foghorn Therapeutics|FHTX - Company Value to Net Income|Forward P/E Multiple Foghorn Therapeutics Inc.|FHTX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Foghorn Therapeutics, Inc.|FHTX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Foghorn Therapeutics|FHTX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months foghorntx.com|FHTX - Earnings per share trend in current year|Earnings growth forecast for next year Foghorn Therapeutics

- revenue and sales proceeds data:

FHTX - Company Total Revenue|Company Future Sales Volume Foghorn Therapeutics, Inc.|FHTX - P/S Multiple|Forward Price-to-Revenue Multiple Foghorn Therapeutics Inc.

Summary company analysis:FHTX (Foghorn Therapeutics, Inc.)

Original product of Foghorn Therapeutics Inc.

Assessing the investment reliability of equity assets begins with an analysis of the ratio of business market value to expected revenue. This metric measures the capitalization multiple relative to projected sales, which, in the case of Foghorn Therapeutics (FHTX) and its outsourcing of clinical trials, allows for the offsetting of operating expenses and the evaluation of genetic research potential via the projected P/S value.

Competitor analysis for Foghorn Therapeutics

TG Therapeutics - Forward Price-to-Revenue Multiple|Forward P/S Multiple Arcellx Therapeutics ACLX|discmedicine.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio syndax.com|Kura Oncology (KURA) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple ADC Therapeutics Corp|VOR (Vor Bio) - Forward P/S Multiple|NKTX: Forward Price to Sales|Forward Price-to-Revenue Multiple COEP (Coeptis Therapeutics)|Actinium Pharmaceuticals - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Estrella Immunopharma, Inc. ESLA|CASI (CASI Pharmaceuticals, Inc) - Future Price to Revenue|MRKR: Forward Price-to-Revenue Multiple|INAB - Forward P/S Multiple|ERNA (eternatx.com) - Forward Price-to-Revenue Multiple|GT Biopharma, Inc. - Forward Price to Sales|APTO (Aptose Biosciences) - Forward P/S Multiple|BPTH: Forward Price to Sales|Forward P/S Multiple MEIP|VINC (Vincerx Pharma) - Forward Price to Sales